
Artificial Intelligence in Pharma and Biotech
MIT Sloan School of Management
The MIT Sloan School of Management, the business school of the Massachusetts Institute of Technology, was formally established in 1952, though its roots trace back to a 1914 engineering administration curriculum — reflecting MIT's conviction that management is, at its core, a rigorous discipline. Located in Cambridge, Massachusetts, it is a university-affiliated school embedded within one of the world's foremost research universities, and that proximity is not incidental — it defines Sloan's entire academic identity. The school operates on the principle that management education should be grounded in analytical frameworks and empirical evidence rather than anecdote, a philosophy that shapes everything from how courses are designed to how faculty are hired. Today, MIT Sloan remains one of a small number of schools where you will find economists, computer scientists, and organizational psychologists contributing directly to the same executive programs. ## Accreditations and Rankings **Accreditations:** - AACSB accredited - EQUIS accredited - AMBA accredited - *(Triple Crown accredited)* **Rankings:** - **Financial Times Global MBA Ranking:** #5 (2024) - **QS World University Rankings — Business & Management Studies:** #4 globally (2024) - **Bloomberg Businessweek MBA Ranking:** #6 (2023) - **Financial Times Executive Education Open Programs:** Consistently ranked in the global top 10 ## Executive Education at a Glance MIT Sloan Executive Education is one of the most programmatically diverse offerings in the world, running more than 90 open enrollment programs annually alongside a substantial custom programs portfolio serving organisations ranging from sovereign wealth funds to global technology companies. The school is particularly known for executive education in areas where management intersects with technology: artificial intelligence strategy, digital transformation, sustainability, system dynamics, and financial innovation. Program formats span intensive on-campus residentials in Cambridge, fully online programs through the MIT Sloan online platform, and blended formats — with durations ranging from two-day intensives to multi-month certificate tracks. Flagship programs include the *Artificial Intelligence: Implications for Business Strategy* program, the *Executive Program in General Management*, and the *System Dynamics for Business Policy* course — the last a direct product of MIT's legendary System Dynamics Group, founded by Jay Forrester. Open program fees typically range from approximately $3,500 for shorter courses to over $15,000 for extended programs, with some certificate programs carrying additional costs. ## Campus and Facilities MIT Sloan's primary executive education activities are anchored in the MIT campus in Cambridge, Massachusetts — a dense, walkable research environment where a five-minute walk can take you past robotics labs, quantum computing centres, and media innovation studios. The main Sloan building, E62, opened in 2010 and was designed by Fumihiko Maki to house a genuinely collaborative environment, with tiered classrooms, informal meeting spaces, and direct sightlines between floors that are intended to produce accidental conversations. For executive participants, Cambridge itself functions as a live case study: the Route 128 technology corridor, the Kendall Square biotech cluster, and the broader Boston ecosystem mean that site visits, alumni dinners, and industry panels are woven directly into the program experience. There are few cities in the world where a conversation at dinner is as likely to involve a Nobel laureate or a first-time founder. ## Faculty and Research MIT Sloan's faculty of roughly 150 senior professors spans economics, finance, operations, organisational behaviour, and — unusually for a business school — deep technical disciplines in data science and systems engineering. The school houses several research centres of direct relevance to executive participants: the MIT Initiative on the Digital Economy (IDE), the Sloan Finance Group, the MIT Leadership Center, and the Center for Information Systems Research (CISR), which has produced some of the most-cited work on digital business models and IT governance. Faculty members like Daron Acemoglu (economics of technology and inequality), Erik Brynjolfsson (digital economy), and Deborah Ancona (distributed leadership) publish work that regularly reshapes boardroom conversations — and they teach in executive programs. The school's explicit expectation is that faculty bring their active research agenda into the classroom, not a polished summary of someone else's. ## Student Body, Alumni, and Career Outcomes Executive education cohorts at MIT Sloan are notably international, typically drawing participants from more than 40 countries across a single program run, with strong representation from North America, Asia-Pacific, and the Middle East. The broader MIT Sloan alumni network numbers over 90,000 graduates across more than 90 countries, with particularly heavy concentrations in technology, financial services, consulting, and advanced manufacturing. Notable alumni include Kofi Annan (former UN Secretary-General), Benjamin Netanyahu (former Israeli Prime Minister and Sloan Fellow), Carly Fiorina (former CEO, Hewlett-Packard), and John Reed (former CEO, Citicorp) — a list that reflects the school's historical pull among both private sector leaders and public sector figures. For executive education participants, outcomes tend to be measured less in placement statistics and more in organisational impact: MIT Sloan's post-program research suggests that custom clients report measurable changes in strategic decision-making processes within 12 months of program completion.
Available Cohorts
Choose your preferred start date
All-inclusive program fee
Duration
7 weeks
Format
online
Topic
Data & AI
Language
English
About This Program
Disruption has arrived in the pharmaceutical and biotech industry. Driven by artificial intelligence (AI) and machine learning (ML) technologies, new possibilities include everything from molecular design to predictive patient reaction models. However, despite a clear connection between the science of drug discovery, ML, and business decision making, there is a disconnect between the tools that exist and the specialists utilizing them. It’s only by bridging this gap that the full potential of this technology will be realized. In the Artificial Intelligence in Pharma and Biotech online short course from MIT Sloan School of Management, you’ll discover the benefits and challenges of AI tools within this sector. Over six weeks, gain insight into the current state of technology in the industry and explore ways that it can be applied to the drug discovery and distribution processes. You’ll learn how AI can be utilized in biological and generative modeling, and examine the impact of ML on the design and management of clinical trials. With insights into the relevance, practical implications, and business impact of these technologies, you’ll be able to position yourself ahead of the curve as innovation reshapes the industry.
Over the course of six weeks, dive into the existing and potential applications of AI and ML in the pharmaceutical and biotech industry. Guided by expert MIT faculty, you’ll gain insight into the optimal AI tools for this industry and explore how they can be leveraged for early drug discovery. Unpack AI’s potential to help promote research efforts into biology and diseases on a cellular level, and how it can assist with tasks like biomarker identification and disease tracking. Finally, you’ll investigate the impact of new AI modalities on patient stratification, and assess the limitations and promises of using ML in the design and management of clinical trials. You’ll walk away from the program with an understanding of AI’s broader business implications for the pharma and biotech industry.
Harness AI for business: Understand how AI and ML can be applied across pharma and biotech organizations.
Leverage new technology: Learn to use ML in the early stages of drug discovery, identifying molecules, designing clinical trials, and selling pharmaceuticals.
Make optimal decisions: Make more informed decisions using ML processes in the science of drug discovery.
Drive industry innovation: Uncover the infinite applications of AI in biotech and discover how they can be applied in your business context.
Why MIT Sloan School of Management?
Your Profile
- This program is designed for business leaders in pharmaceutical science and other scientific fields who want to understand how AI can be integrated into their organization. The program is ideal for professionals who are interested in the various AI and ML tools available, and want to learn how to apply them in their research and work. Researchers, specialists, data scientists, software developers and analysts working for a pharmaceutical company will also benefit from the course as they learn the broader business implications of AI applications in pharma and biotech, and how these technologies can be introduced within their context.
Benefits
- Harness AI for business: Understand how AI and ML can be applied across pharma and biotech organizations.
- Leverage new technology: Learn to use ML in the early stages of drug discovery, identifying molecules, designing clinical trials, and selling pharmaceuticals.
- Make optimal decisions: Make more informed decisions using ML processes in the science of drug discovery.
- Drive industry innovation: Uncover the infinite applications of AI in biotech and discover how they can be applied in your business context.
What You'll Learn
- The Landscape of Artificial Intelligence (AI) in the Pharmaceutical Industry
- Using AI for Early Drug Discovery: From Small Molecules to Biologics
- Modeling the Biological Underpinning of Disease
- Biomarkers, Discovery, and Patient Stratification
- Design and Management of Clinical Trials
- Business and Innovation in Pharma